Anthropic Partners With Six Firms to Speed Drug Development
Anthropic's life sciences team has partnered with six organizations, including Bristol Myers Squibb, Generate Biomedicines, and Divergence Labs, to accelerate drug development using Claude. The partnerships span disease areas including cancer, food allergies, and rare childhood diseases. Notable early results include a CAR T-cell therapy component redesigned to be 70% shorter and 10 times more effective at producing receptors, and roughly 35,000 antibody designs generated in a month for a food allergy treatment, yielding promising early hits. Anthropic has also launched its own drug discovery programs, including efforts targeting rare childhood muscular dystrophy.
Anthropic bought a one-person drug company and, if results hold up, expects human trials by late 2028.
